<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798819</url>
  </required_header>
  <id_info>
    <org_study_id>GLS-010-32</org_study_id>
    <nct_id>NCT05798819</nct_id>
  </id_info>
  <brief_title>A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Gloria Biosciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Gloria Biosciences Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010&#xD;
      plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for&#xD;
      persistent, recurrent, or metastatic cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled phase III study，aimed to evaluate the&#xD;
      efficacy and safety of GLS-010 plus platinum-containing chemotherapy with or without&#xD;
      bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical&#xD;
      cancer.All enrolled patients will be randomly divided into 2 groups and continuously treated&#xD;
      until any event that meets the criteria for end of the clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2023</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Proportion of subjects who have a complete or partial response relative to baseline based on RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR defined as the proportion of subjects' response of CR, PR, or SD based on RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response（TTR）</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>TTR defined as the time from the date of randomization to the date when the response criteria are first met, based on RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>From the time of signed informed consent to 90 days after end of treatment.</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>EORTC QLQ-C30 will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">424</enrollment>
  <condition>Persistent, Recurrent, or Metastatic Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>GLS-010+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-010 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS-010</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>GLS-010+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>GLS-010+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>GLS-010+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>GLS-010+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>GLS-010+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent form.&#xD;
&#xD;
          2. Women aged ≥ 18 and ≤ 75 years.&#xD;
&#xD;
          3. ECOG of 0 or 1.&#xD;
&#xD;
          4. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          5. Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1),.The&#xD;
             histological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous&#xD;
             cell carcinoma.&#xD;
&#xD;
          6. No prior systemic therapy for persistent, recurrent or metastatic ([FIGO] Stage IVB)&#xD;
             disease,not amenable to curative surgery or concurrent chemoradiotherapy.&#xD;
&#xD;
          7. At least one measurable tumor lesion per RECIST v1.1; lesions previously treated with&#xD;
             radiotherapy or other loco-regional therapy are not considered as target lesions&#xD;
             unless the lesion has unequivocal progression or the biopsy is obtained to confirm&#xD;
             maligancy.&#xD;
&#xD;
          8. Subjects must have adequate organ function.&#xD;
&#xD;
          9. Female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
             prior to the first dose. Female subject of childbearing potential must use acceptable&#xD;
             effective methods of contraception from screening and must agree to continue these&#xD;
             precautions until 6 months after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with the opportunity to be cured by surgery and radiotherapy.&#xD;
&#xD;
          2. Received with concurrent chemoradiotherapy, adjuvant chemotherapy,neo- adjuvant&#xD;
             chemotherapy within 4 weeks prior to randomization.&#xD;
&#xD;
          3. Active central nervous system (CNS) metastasis.&#xD;
&#xD;
          4. Patients with other malignancies prior to randomization. Note: Participants with basal&#xD;
             cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell&#xD;
             carcinoma of urothelial cancer, or carcinoma in situ (e.g. breast cancer) that have&#xD;
             been cured are not excluded.&#xD;
&#xD;
          5. Has an active autoimmune disease that has required systemic treatment.&#xD;
&#xD;
          6. With active serious infections.&#xD;
&#xD;
          7. Subjects with HIV infection ,active hepatitis B virus infection, active hepatitis C&#xD;
             virus infection,active tuberculosis infection,active syphilis .&#xD;
&#xD;
          8. Has not recovered adequately from toxicity and/or complications from surgery prior to&#xD;
             randomization.&#xD;
&#xD;
          9. . .&#xD;
&#xD;
         10. Has a contraindication or hypersensitivity to any component of cisplatin, carboplatin,&#xD;
             paclitaxel, or bevacizumab.&#xD;
&#xD;
         11. Have received any investigational treatment in other clinical trials within 4 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
         12. Pregnant or lactating women,or women may become pregnant during treatment.&#xD;
&#xD;
         13. Has had an allogeneic tissue/solid organ/ hematopoietic stem cells transplant.&#xD;
&#xD;
         14. History of nervous system and mental disease. History of drug abuse.&#xD;
&#xD;
         15. The patient is not suitable to participate the study in the opinion of the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>December 26, 2022</study_first_submitted>
  <study_first_submitted_qc>April 4, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

